Geovani Faddoul1, Girish N Nadkarni1, Nancy D Bridges2, Jens Goebel3, Donald E Hricik4, Richard Formica5, Madhav C Menon1, Yvonne Morrison2, Barbara Murphy1, Kenneth Newell6, Peter Nickerson7, Emilio D Poggio8, David Rush7, Peter S Heeger1. 1. Department of Medicine, Translational Transplant Research Center, Recanati Miller Transplant Institute, Immunology Institute Icahn School of Medicine at Mount Sinai, New York, NY. 2. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. 3. Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 4. Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH. 5. Department of Medicine, Yale University School of Medicine, New Haven, CT. 6. Department of Surgery, Emory University Medical Center, Atlanta, GA. 7. Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. 8. Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH.
Abstract
BACKGROUND: An early posttransplant biomarker/surrogate marker for kidney allograft loss has the potential to guide targeted interventions. Previously published findings, including results from the Clinical Trials in Organ Transplantation (CTOT)-01 study, showed that elevated urinary chemokine CXCL9 levels and elevated frequencies of donor-reactive interferon gamma (IFNγ)-producing T cells by enzyme-linked immunosorbent spot (ELISPOT) assay associated with acute cellular rejection within the first year and with lower 1-year posttransplant estimated glomerular filtration rate (eGFR). How well these biomarkers correlate with late outcomes, including graft loss, is unclear. METHODS: In CTOT-17, we obtained 5-year outcomes in the CTOT-01 cohort and correlated them with (a) biomarker results and (b) changes in eGFR (Chronic Kidney Disease Epidemiology Collaboration formula) over the initial 2 years posttransplant using univariable analysis and multivariable logistic regression. RESULTS: Graft loss occurred in 14 (7.6%) of 184 subjects 2 to 5 years posttransplant. Neither IFNγ ELISPOTs nor urinary CXCL9 were informative. In contrast, a 40% or greater decline in eGFR from 6 months to 2 years posttransplant independently correlated with 13-fold odds of 5-year graft loss (adjusted odds ratio, 13.1; 95% confidence interval, 3.0-56.6), a result that was validated in the independent Genomics of Chronic Allograft Rejection cohort (n = 165; adjusted odds ratio, 11.2). CONCLUSIONS: We conclude that although pretransplant and early posttransplant ELISPOT and chemokine measurements associate with outcomes within 2 years posttransplant, changes in eGFR between 3 or 6 months and 24 months are better surrogates for 5-year outcomes, including graft loss.
BACKGROUND: An early posttransplant biomarker/surrogate marker for kidney allograft loss has the potential to guide targeted interventions. Previously published findings, including results from the Clinical Trials in Organ Transplantation (CTOT)-01 study, showed that elevated urinary chemokine CXCL9 levels and elevated frequencies of donor-reactive interferon gamma (IFNγ)-producing T cells by enzyme-linked immunosorbent spot (ELISPOT) assay associated with acute cellular rejection within the first year and with lower 1-year posttransplant estimated glomerular filtration rate (eGFR). How well these biomarkers correlate with late outcomes, including graft loss, is unclear. METHODS: In CTOT-17, we obtained 5-year outcomes in the CTOT-01 cohort and correlated them with (a) biomarker results and (b) changes in eGFR (Chronic Kidney Disease Epidemiology Collaboration formula) over the initial 2 years posttransplant using univariable analysis and multivariable logistic regression. RESULTS:Graft loss occurred in 14 (7.6%) of 184 subjects 2 to 5 years posttransplant. Neither IFNγ ELISPOTs nor urinary CXCL9 were informative. In contrast, a 40% or greater decline in eGFR from 6 months to 2 years posttransplant independently correlated with 13-fold odds of 5-year graft loss (adjusted odds ratio, 13.1; 95% confidence interval, 3.0-56.6), a result that was validated in the independent Genomics of Chronic Allograft Rejection cohort (n = 165; adjusted odds ratio, 11.2). CONCLUSIONS: We conclude that although pretransplant and early posttransplant ELISPOT and chemokine measurements associate with outcomes within 2 years posttransplant, changes in eGFR between 3 or 6 months and 24 months are better surrogates for 5-year outcomes, including graft loss.
Authors: Jennifer L Lee; Cyd K Eaton; Kristin Loiselle Rich; Bonney Reed-Knight; Rochelle S Liverman; Laura L Mee; Ana M Gutierrez-Colina; Rene Romero; Ronald L Blount Journal: Health Psychol Date: 2016-12-08 Impact factor: 4.267
Authors: Donald E Hricik; Richard N Formica; Peter Nickerson; David Rush; Robert L Fairchild; Emilio D Poggio; Ian W Gibson; Chris Wiebe; Kathryn Tinckam; Suphamai Bunnapradist; Milagros Samaniego-Picota; Daniel C Brennan; Bernd Schröppel; Osama Gaber; Brian Armstrong; David Ikle; Helena Diop; Nancy D Bridges; Peter S Heeger Journal: J Am Soc Nephrol Date: 2015-04-29 Impact factor: 10.121
Authors: M Rabant; L Amrouche; L Morin; R Bonifay; X Lebreton; L Aouni; A Benon; V Sauvaget; L Le Vaillant; F Aulagnon; R Sberro; R Snanoudj; A Mejean; C Legendre; F Terzi; D Anglicheau Journal: Am J Transplant Date: 2016-03-10 Impact factor: 8.086
Authors: Ingeborg A Hauser; Sandra Spiegler; Eva Kiss; Stefan Gauer; Olaf Sichler; Ernst H Scheuermann; Hanns Ackermann; Josef M Pfeilschifter; Helmut Geiger; Hermann-Josef Gröne; Heinfried H Radeke Journal: J Am Soc Nephrol Date: 2005-04-27 Impact factor: 10.121
Authors: A Hart; J M Smith; M A Skeans; S K Gustafson; D E Stewart; W S Cherikh; J L Wainright; A Kucheryavaya; M Woodbury; J J Snyder; B L Kasiske; A K Israni Journal: Am J Transplant Date: 2017-01 Impact factor: 8.086
Authors: Herwig-Ulf Meier-Kriesche; Bettina J Steffen; Alice H Chu; Jacqueline J Loveland; Robert D Gordon; Jonathan A Morris; Bruce Kaplan Journal: Am J Transplant Date: 2004-12 Impact factor: 8.086
Authors: Huaizhong Hu; Brian D Aizenstein; Alice Puchalski; Jeanine A Burmania; Majed M Hamawy; Stuart J Knechtle Journal: Am J Transplant Date: 2004-03 Impact factor: 8.086
Authors: Zhongyang Zhang; Zeguo Sun; Jia Fu; Qisheng Lin; Khadija Banu; Kinsuk Chauhan; Marina Planoutene; Chengguo Wei; Fadi Salem; Zhengzi Yi; Ruijie Liu; Paolo Cravedi; Haoxiang Cheng; Ke Hao; Philip J O'Connell; Shuta Ishibe; Weijia Zhang; Steven G Coca; Ian W Gibson; Robert B Colvin; John Cijiang He; Peter S Heeger; Barbara Murphy; Madhav C Menon Journal: J Clin Invest Date: 2021-11-15 Impact factor: 14.808
Authors: Wiebke Sommer; Jane M O; Kurt B Pruner; Abbas Dehnadi; Kyu Ha Huh; Kortney A Robinson; Isabel Hanekamp; Ivy Rosales; Alison S Bean; Josh Paster; Tetsu Oura; Rex Neal Smith; Robert Colvin; Gilles Benichou; Tatsuo Kawai; Joren C Madsen; James S Allan Journal: Transplant Direct Date: 2021-05-25
Authors: Tara K Sigdel; Joshua Y C Yang; Oriol Bestard; Andrew Schroeder; Szu-Chuan Hsieh; Juliane M Liberto; Izabella Damm; Anna C M Geraedts; Minnie M Sarwal Journal: PLoS One Date: 2019-07-31 Impact factor: 3.240